Follicular lymphoma trials in Italy

In Italy 25 Also abroad 188

25 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Where
Brescia, Meldola, Milan, Naples, Rozzano
Age
18 years and over
People
130 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00
Phase 1/2Taking people
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Where
Candiolo, Milan, Naples, Reggio Emilia, Rome, Rozzano
Age
18 years and over
People
280 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00
Phase 2/3Taking people
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Where
Candiolo, Rome
Age
18 years and over
People
960 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07634471 · EU 2025-522777-10-00
Phase 1Taking people
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Where
Bologna, Naples, Rozzano
Age
18 years and over
People
215 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07101328 · EU 2025-524180-20-00
Phase 1Taking people
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
Bologna, Milan
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 1Taking people
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Where
Candiolo, Milan
Age
18 years and over
People
140 worldwide
Run by
Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659
Phase 1Taking people
A Study of ARC-02 in B-cell NHL
Where
Aviano, Bergamo, Bologna, Rozzano
Age
18 years and over
People
140 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00
Phase 3Taking people
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Where
Bologna, Guastalla, Milan, Rozzano, Trieste
Age
18 years to 130 years
People
1,018 worldwide
Run by
AstraZeneca
See details and how to joinNCT06549595 · EU 2023-510098-33-01
Phase 2Taking people
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Where
Alexandria, Bologna, Busto Arsizio, Milan
Age
18 years and over
People
270 worldwide
Run by
AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00
Phase 3Taking people
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Where
Aviano, Bologna, Brescia, Candiolo, Genoa, Meldola, Milan, Modena, Monza, Naples, Novara, Pavia, Perugia, Ravenna, Reggio Emilia, Rome, Turin, Udine
Age
18 years and over
People
580 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06149286 · EU 2022-503092-28-00
Phase 3Taking people
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Where
Ascoli Piceno, Bologna, Brescia, Candiolo, Genoa, Meldola, Milan, Naples, Novara, Ravenna, Tricase, Udine, Varese
Age
18 years and over
People
822 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091254 · EU 2022-502660-20-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Bologna, Milan, Roma, Verona
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 1/2Taking people
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Where
Bologna, Milan
Age
18 years and over
People
174 worldwide
Run by
AstraZeneca
See details and how to joinNCT06542250
Phase 3Taking people
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
Where
Alessandria, Avellino, Aviano, Bari, Biella, Brescia, Cagliari, Candiolo, Castelfranco Veneto, Catania, Cuneo, Florence, Ivrea, Latina, Meldola, Messina, Milan, Modena, Monza, Naples, Novara, Padova, Palermo, Pavia, Perugia, Piacenza, Pisa, Ravenna, Reggio Emilia, Rimini, Roma, Sassuolo, Siena, Sondrio, Terni, Treviso, Udine, Varese, Verona
Age
18 years and over
People
190
Run by
Fondazione Italiana Linfomi - ETS
See details and how to joinNCT05929222
Phase 2Taking people
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Where
Bologna, Milan, Naples
Age
18 years and over
People
120 worldwide
Run by
Universität Münster
See details and how to joinNCT07197307 · EU 2023-509861-19-01
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Bologna, Brescia, Milan, Rome
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
Phase 3Taking people
Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial.
Where
Alexandria, Avellino, Aviano, Bari, Brescia, Cagliari, Candiolo, Castelfranco Veneto, Catania, Chivasso, Cuneo, Florence, Latina, Meldola, Messina, Milan, Modena, Monza, Naples, Novara, Padova, Palermo, Pavia, Perugia, Piacenza, Pisa, Ponderano, Ravenna, Reggio Emilia, Rimini, Roma, Rome, Sassuolo, Siena, Sondrio, Terni, Treviso, Udine, Varese, Verona
Age
18 years and over
People
190
Run by
Fondazione Italiana Linfomi Onlus
See details and how to join2022-502775-29-01 · EU 2022-502775-29-01
Phase 2Taking people
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Where
Turin
Age
18 years to 70 years
People
213 worldwide
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Where
Alexandria, Bologna, Meldola, Naples, Pisa, Rozzano, Turin
Age
18 years and over
People
400 worldwide
Run by
Celgene
See details and how to joinNCT06911502 · EU 2024-519152-82-00
No phaseNot yet taking people in Italy
Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
Where
Ancona, Avellino, Aviano, Bari, Brescia, Cagliari, Florence, Milan, Monza, Padova, Palermo, Parma, Piacenza, Prato, Ravenna, Reggio Emilia, Roma, Siena, Teramo, Torino, Udine, Verona
Age
70 years and over
People
170
Run by
Fondazione Italiana Linfomi - ETS
See details and how to joinNCT07476105
No phaseTaking people
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Where
Bari, Milan, Naples, Palermo, Rome, Turin
Age
18 years and over
People
700 worldwide
Run by
AbbVie
See details and how to joinNCT06830759
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
Alexandria, Milan, Turin, Verona
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
No phaseTaking people
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
Where
Milan
Age
18 years and over
People
25
Run by
Andrés José Maria Ferreri
See details and how to joinNCT07278921
No phaseTaking people
Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
Where
Alessandria, Biella, Brescia, Catania, Cuneo, Florence, Genova, Meldola, Milan, Modena, Monza, Novara, Pagani, Palermo, Pavia, Piacenza, Reggio Calabria, Rimini, Roma, Rozzano, Torino, Tricase, Udine, Varese
Age
18 years and over
People
654
Run by
Fondazione Italiana Linfomi - ETS
See details and how to joinNCT05816850
No phaseTaking people
Italian Observational Study on CAR-T Therapy for Lymphoma
Where
Milan
Age
18 years and over
People
5,300
Run by
Paolo Corradini
See details and how to joinNCT06339255